Reopening the fund gives the investment team the ability to take advantage of current market conditions, said Scott Benjamin, senior vice president and head of product and marketing for Jennison Dryden. A confluence of medical, regulatory, legal and market trends offers unprecedented opportunity for the funds seasoned healthcare team to make investment choices that give investors the potential for financial growth, particularly over the long-term.
Specifically, the funds managers anticipate new product approvals, regulatory developments, and significant mergers or partnerships and market dynamics.
The fund seeks long-term capital appreciation by investing in the stocks of companies primarily engaged in the drug, healthcare, medicine, medical devices, and biotechnology industries.
